Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
26 5월 2023 - 9:00PM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the
Company”), a clinical-stage biotechnology company developing novel
LAG-3 immunotherapies for cancer and autoimmune disease, today
announces data from Part C of its TACTI-002 Phase II trial has been
published in an abstract available on the 2023 American Society of
Clinical Oncology’s (ASCO) Annual Meeting’s official website. A
Trial in Progress abstract for the Phase II/III AIPAC-003
trial has also been published.
The TACTI-002 poster will contain more mature
(longer follow up) and final data that is not part of the abstract
and will be available on the Posters & Publication section of
Immutep’s website after its presentation at ASCO. Abstracts are
available at ASCO.org.
TACTI-002
AbstractTitle: Final results from
TACTI-002 Part C: A Phase II study of eftilagimod alpha (soluble
LAG-3 protein) and pembrolizumab in patients with metastatic 2nd
line head and neck squamous cell carcinoma unselected for
PD-L1Poster Session: Head and Neck CancerDate and Time: 5 June
2023, 2:15PM-5:15PM EDTPresenter: Dr. Bernard Doger, START
Madrid-FJD, Fundación Jiménez Díaz University Hospital, Madrid,
SpainAbstract #: 6029
AIPAC-003
AbstractTitle: AIPAC-003: A
randomized, double-blind, placebo-controlled phase 3 trial
testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low
metastatic breast cancer patients receiving paclitaxel, following
an open-label dose optimization.Poster Session: Breast Cancer –
Local/Regional/AdjuvantDate and Time: 4 June 2023, 9:00AM-12:00PM
EDTPresenter: Dr. Nuhad K. Ibrahim, Professor, Department of Breast
Medical Oncology, Division of Cancer Medicine, The University of
Texas MD Anderson Cancer Center, Houston, TXAbstract #: TPS1120
About Eftilagimod Alpha (Efti)
Efti is Immutep’s proprietary soluble LAG-3
protein and MHC Class II agonist that stimulates both innate and
adaptive immunity for the treatment of cancer. As a first-in-class
antigen presenting cell (APC) activator, efti binds to MHC (major
histocompatibility complex) Class II molecules on APC leading to
activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper
T cells, dendritic cells, NK cells, and monocytes. It also
upregulates the expression of key biological molecules like IFN-ƴ
and CXCL10 that further boost the immune system’s ability to fight
cancer.
Efti is under evaluation for a variety of solid
tumours including non-small cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its
favourable safety profile enables various combinations, including
with anti-PD-[L]1 immunotherapy and/or chemotherapy. Efti has
received Fast Track Designation in 1st line HNSCC and in 1st line
NSCLC from the United States Food and Drug Administration
(FDA).
About ImmutepImmutep is a
clinical stage biotechnology company developing novel LAG-3
immunotherapy for cancer and autoimmune disease. We are pioneers in
the understanding and advancement of therapeutics related to
Lymphocyte Activation Gene-3 (LAG-3), and our diversified product
portfolio harnesses its unique ability to stimulate or suppress the
immune response. Immutep is dedicated to leveraging its expertise
to bring innovative treatment options to patients in need and to
maximise value for shareholders. For more information, please visit
www.immutep.com.
Australian
Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406
759 268; cstrong@citadelmagnus.com
U.S. Media:Chris Basta, VP,
Investor Relations and Corporate Communications+1 (631) 318 4000;
chris.basta@immutep.com
Immutep (NASDAQ:IMMP)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Immutep (NASDAQ:IMMP)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024